MuSK-CAART: A novel precision cellular therapy for muscle-specific tyrosine kinase myasthenia gravis

Precision cellular therapy for MuSK myasthenia gravis

Authors

DOI:

https://doi.org/10.17161/rrnmf.v4i3.19417

Keywords:

autoimmunity, neurology, immunotherapy, CAR T cells, neuromuscular junction

Abstract

Chimeric autoantibody receptor (CAAR) T cells are a novel genetically-engineered T cell immunotherapy that aims to durably eliminate antigen-specific B cells while sparing healthy B cells, ideally leading to safe and lasting remission of B cell-mediated autoimmune diseases with a one-time infusion. We describe the preclinical development of muscle-specific tyrosine kinase CAAR T cells (MuSK-CAART) for the treatment of MuSK myasthenia gravis, a debilitating autoantibody-mediated disease that causes potentially life-threatening muscle weakness.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biography

Sangwook Oh, University of Pennsylvania

Senior Research Investigator, Department of Dermatology, University of Pennsylvania

Downloads

Published

2023-08-29

How to Cite

Payne, A., & Oh, S. (2023). MuSK-CAART: A novel precision cellular therapy for muscle-specific tyrosine kinase myasthenia gravis : Precision cellular therapy for MuSK myasthenia gravis. RRNMF Neuromuscular Journal, 4(3). https://doi.org/10.17161/rrnmf.v4i3.19417

Issue

Vol. 4 No. 3 (2023): Proceedings of the MGFA International Conference

Section

MGFA International Conference Proceedings

License

Copyright (c) 2023 Aimee Payne, Sangwook Oh

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.